Autoantibodies in the diagnosis, prognosis, and prediction of colorectal cancer

• Published in: Journal of cancer research and therapeutics Vol. 17; no. 4; pp. 819 - 833
• Main Authors: Niloofa, Roshan, De Zoysa, M, Seneviratne, L
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.07.2021; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Animals; Autoantibodies; Autoantibodies - blood; Autoantibodies - immunology; Biological markers; Colorectal cancer; Colorectal Neoplasms - blood; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - immunology; Diagnosis; Health aspects; Humans; Prognosis; Risk factors; Sri Lanka; Anti-p53; colorectal cancer; early detection; tumor-associated antigen; autoantibodies; prognosis
• ISSN: 0973-1482; 1998-4138
• DOI: 10.4103/jcrt.JCRT_64_19

Colorectal cancer (CRC) is the second-most commonly diagnosed cancer worldwide. Early diagnosis improves prognosis and long-term outcomes. Several studies have found tumor-associated autoantibodies in CRC patients. We aimed to provide an overview on CRC-associated autoantibodies and their reported diagnostic, prognostic, and predictive performance when used singly or in combination. We systematically reviewed studies on CRC-related autoantibodies published till March 2018 and critically analyzed the role of these autoantibodies in CRC. In general, autoantibodies were of low sensitivity when tested individually and the diagnostic characteristics improved when tested in combination. Autoantibodies against CCD83, carcinoembryonic antigen, MAPKAPK3, RPH 3AL, SEC61b, and SPAG9 showed high sensitivity and specificity when tested alone. When tested in combination, autoantibodies against three antigens (PIM1, MAPKAPK3, and ACVR2B) showed high sensitivity and specificity. So far, most CRC-associated autoantibodies have been evaluated in single or in a small number of studies. In contrast, anti-p53 antibodies have been studied in a larger number of CRC studies, but, so far, none of them have high diagnostic characteristics. CRC-associated autoantibodies are detectable from the early stages of malignancy, pointing to their possible use in the early detection of CRC. Some studies suggest that CRC-associated autoantibodies may be a guide to prognosis in CRC.